MedTrace Logo

Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events

NCT00206089 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3300

Last updated 2010-11-15

No results posted yet for this study

Summary

This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks. A separate visit, independent from the study will be done approximately 6 months after the surgery.

Conditions

  • Thromboembolism

Interventions

DRUG

EXANTA

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • Austria
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Hungary
  • Mexico
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • South Africa
  • Spain
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206089 on ClinicalTrials.gov